Improve Research Reproducibility A Bio-protocol resource
  • search
  • 提交稿件
  • 订阅
  • CN change language
Peer-reviewed

Methods to Detect AUTOphagy-Targeting Chimera (AUTOTAC)-mediated Targeted Protein Degradation in Tauopathies

在tau蛋白病变中检测自噬-靶向嵌合体(AUTOTAC)介导的靶向蛋白降解的方法

ML Min Ju Lee *
SK Su Bin Kim *
HK Hee Yeon Kim *
SL Su Jin Lee *
JL Ji Su Lee
YK Yong Tae Kwon
CJ Chang Hoon Ji

 (*contributed equally to this work) 发布: 2023年01月20日第13卷第2期 DOI: 10.21769/BioProtoc.4594 浏览次数: 1573

评审: Gal HaimovichHyeong-Reh Choi KimNingfei An

download pdf 下载 PDF 下载 PDF
ask Q&A
引用
收藏
Cited by

参见作者原研究论文

The authors used this protocol in:

Cover of Nature Communications, featuring study using the protocol.

Feb 2022

Presubmission Inquiry

实验方案合集

专注于特定技术或应用的、详细的、经过同行评审的实验方案合集

Cancer Research
Immunology
Developmental Biology
Microbiology
Neuroscience
Cell Imaging - A Special Collection for Cell Bio 2023
查看更多 more

相关实验方案

人来源iPSC获得的神经祖细胞(NPCs)的产生作为神经和线粒体疾病的药物发现模型

人来源iPSC获得的神经祖细胞(NPCs)的产生作为神经和线粒体疾病的药物发现模型

Annika Zink [...] Alessandro Prigione

2021年03月05日 7488 阅读

妊娠晚期短暂性产前缺氧的简化范式研究发育性低氧损伤的功能和结构结果

妊娠晚期短暂性产前缺氧的简化范式研究发育性低氧损伤的功能和结构结果

Elyse C. Gadra and Ana G. Cristancho

2022年10月05日 1417 阅读

使用新型荧光标记物DAPRed对活细胞中的自噬通量进行实时测量

使用新型荧光标记物DAPRed对活细胞中的自噬通量进行实时测量

Arnold Sipos [...] Edward D. Crandall

2024年03月05日 1179 阅读

Abstract

Targeted protein degradation (TPD) facilitates the selective elimination of unwanted and pathological cellular cargoes via the proteasome or the lysosome, ranging from proteins to organelles and pathogens, both within and outside the cell. Currently, there are several in vitro and in vivo protocols that assess the degradative potency of a given degrader towards a myriad of targets, most notably soluble, monomeric oncoproteins. However, there is a clear deficiency of methodologies to assess the degradative potency of heterobifunctional chimeric degraders, especially those in the autophagy space, against pathological, mutant tau species, such as detergent-insoluble oligomers and high-molecular aggregates. The protocol below describes both in vitro and in vivo biochemical assays to induce tau aggregation, as well as to qualitatively and quantitatively measure the degradative potency of a given degrader towards said aggregates, with specific applications of the AUTOTAC (AUTOphagy-TArgeting Chimera) platform provided as an example. A well-defined set of methodologies to assess TPD-mediated degradation of pathological tau species will help expand the scope of the TPD technology to neurodegeneration and other proteinopathies, in both the lab and the clinic.


Graphical abstract



Overview of assays observing elimination of tauP301L aggregates with AUTOTAC. (A) Description of the biological working mechanism of heterobifunctional chimeric AUTOTAC degraders. (B) Schematic illustration of assays described in this paper.

Keywords: TPD (TPD) search AUTOTAC (AUTOTAC) search Detergent-insoluble/soluble fractionation (去污剂-不溶性/可溶性分馏) search in vivo oligomerization (体内低聚物化) search Lysosomal acidification (溶酶体酸化) search hTauP301L-BiFC (hTauP301L-BiFC) search

Background

Targeted protein degradation (TPD) is a global protein editing tool with the potential to modulate the half-life of any proteinaceous cargoes (Chamberlain and Hamann, 2019). In addition to serving as a research tool for protein degradation and function, TPD offers an alternative—and thus attractive—means to eradicate disease-causing agents, especially those entrenched in the previously-considered undruggable proteome (Moon and Lee, 2018; Fisher and Phillips, 2018; Schapira et al., 2019; Ji et al., 2022). The various TPD platforms to date harness either the proteasome or the lysosome to facilitate the targeted elimination of a wide variety of cargoes, both within and outside the cell via distinct mechanisms, exemplified by PROteolysis-Targeting Chimera (PROTAC), Antibody-based proTAC (AbTAC), Lysosome-Targeting Chimera (LYTAC), Autophagy-Targeting Chimera (AUTAC), and AuTophagosome-TEthering Compound (ATTEC), to name just a few (Takalo et al., 2013; Thibaudeau et al., 2018; Takahashi et al., 2019; Li et al., 2019; Banik et al., 2020).

Despite the rapid development of TPD platforms with distinct mechanisms of action, the large majority of focus has been centered around a relatively few number of targets, mostly oncoproteins. Even with the emergence of autophagy/lysosome-based degraders, efficient degradation has been limited to only a handful of alternative targets—especially those responsible for neurodegeneration and proteopathies in general. Consequently, development of novel autophagy-based degraders that can target a wide range of pathological hallmark proteins of neurodegeneration and proteopathies, most notably their high-molecular weight, oligomeric, aggregated, and amyloidogenic species, still remains a pressing issue. A notable obstacle to such development is the relative lack of in vitro and in vivo methodologies to analyze in depth the degradative potency and mechanism of action of such degraders. Such difficulty is exacerbated by the fact that, unlike oncoproteins, the downstream signaling cascades of hallmark proteins of neurodegeneration/proteopathies still remain murky, which accentuates even further the importance of well-defined, precise assays and models to assess the autophagic mechanism of action and potency of an autophagy-based degrader (Peeraer et al., 2015; Lim et al., 2018).

To that end, we have recently reported the development and proof-of-concept characterization of a novel p62-targeting/activating TPD platform called AUTOphagy-TArgeting Chimera (Ji et al., 2022). AUTOTAC degraders can selectively recognize and target a broad range of cellular proteins to autophagic membranes for lysosomal degradation, through the selective interaction and activation of the archetypal autophagy cargo receptor p62/SQSTM1 via its ZZ domain. This interaction induces the conformational activation of inactive p62 into an autophagy-compatible form, which exposes PB1 and LIR domains, and facilitates p62 self-oligomerization in complex with targets and its interaction with LC3 on autophagic membranes (Cha-Molstad et al., 2015; Cha-Molstad et al., 2017; Ji et al., 2017, 2019, 2020; Zhang et al., 2018; Yoo et al., 2018; Heo et al., 2021, 2022). AUTOTAC technology was shown to efficiently degrade both oncoproteins and misfolded, aggregation-prone proteins of neurodegeneration.

In this paper, adopted from our paper describing the proof-of-concept development of the AUTOTAC platform, we describe both in vitro methods and in vivo models to not only induce pathological tau aggregation but also assess the selective degradative potency of a given TPD platform towards said aggregates and fibrils (Ji et al., 2022). To this end, we employed SH-SY5Y-hTauP301L cell lines and murine model that can utilize various fluorescent reporters, including full or split halves of the GFP protein, as well as a tandem mRFP-GFP fusion (Shin et al., 2020). Using these models, we induced the formation of detergent-insoluble, high-molecular weight aggregates of the mutant recombinant tau both in vitro and in vivo. The AUTOTAC TPD platform was shown to successfully degrade these pathological tau species in a lysosome-dependent manner. Overall, the protocol provides a systematic approach to generating pathological tau for the testing of not only AUTOTACs but also other autophagy-based degraders and small-molecule compounds in general, which may be expanded to other hallmark proteins of misfolding and aggregation-prone proteopathies and neurodegeneration.

Materials and Reagents

Part I. In vitro degradation of tauP301L aggregates

  1. 5 mL pipette aid (SPL, catalog number: 91010)

  2. 10 mL pipette aid (SPL, catalog number: 91005)

  3. 1.5 mL e-tube (Axygen, catalog number: MCT-150-C)

  4. 100 mm dish (Nest, catalog number: 704002, SPL, catalog number: 30100)

  5. 6-well plate (Nest, catalog number: 703003, SPL, catalog number: 30006)

  6. 12-well plate (Nest, catalog number: 712003, SPL, catalog number: 30012)

  7. 24-well plate (Nest, catalog number: 702002, SPL, catalog number: 30024)

  8. Kim-wipe or paper towel (Yuhan-Kimberly, catalog number: 41112)

  9. Polyvinylidene difluoride membrane, 0.45 μm (Millipore, catalog number: IPVH00010)

  10. X-ray film (AGFA, catalog number: CP-BU)

  11. Microscope slide (Marienfield, catalog number: 1000612)

  12. Cover glass (Marienfield, catalog number: 0117520)

  13. PBS (Biosesang, catalog number: P2007-1)

  14. DMEM (Life Technologies, Gibco®, catalog number: 11995-065)

  15. RPMI (Life Technologies, Gibco®, catalog number: 22400-089)

  16. Opti-mem (Life Technologies, Gibco®, catalog number: 31984-070)

  17. 0.05% trypsin (Life Technologies, Gibco®, catalog number: 25300)

  18. Lipofectamine 2000 (Invitrogen, catalog number: 11668019)

  19. Sodium dodecyl sulfate (SDS) (Duchefa Biochemie, catalog number: S1377.1000)

  20. Triple-distilled water

  21. 1 M Tris-HCl, pH 6.8 (Biosesang, catalog number: TR2016-050-68)

  22. 1.5 M Tris-HCl, pH 8.8 (Biosesang, catalog number: TR4020-050-88)

  23. APS (Ammonium Persulfate) (Bio-Rad, catalog number: 1610700)

  24. TEMED (Bio-Rad, catalog number: 161-0801)

  25. 2-Propanol (Sigma-Aldrich, catalog number: L53191334)

  26. 5× Laemmli sample buffer (Elpis Biotech, catalog number: EBA-1052)

  27. Skim milk (Georgiachem, catalog number: SM2010)

  28. SuperSignalTM West PICO PLUS (Thermo Fisher Scientific, catalog number: 34578)

  29. PFF (Recombinant Human Tau P301L pre-formed fibrils) (NOVUS, catalog number: NBP2-76794)

  30. Hydroxychloroquine (HCQ) (Sigma, catalog number: A25547)

  31. Okadaic acid (Enzo, catalog number: ALX-350-003-C100)

  32. HEPES (Duchefa Biochemie, catalog number: H1504.011)

  33. PierceTM protein transfection reagent (PJ) (Thermo Fisher Scientific, catalog number: 89850)

  34. NaCl (Duchefa Biochemie, catalog number: S0520.5000)

  35. RIPA (Cell nest, catalog number: CNR001-0100)

  36. PierceTM BCA protein assay kit (Thermo Fisher Scientific, catalog number: 23225)

  37. 4× LDS sample buffer non-reducing (Thermo Fisher Scientific, 84788)

  38. PLL solution (Sigma-Aldrich, catalog number: P4707)

  39. Albumin (Biosesang, catalog number: AC1025-100-00)

  40. Foil (SAM JIN FOIL, 30 cm × 30 m)

  41. Triton X-100 (Sigma-Aldrich, catalog number: T9284)

  42. Antifade-mounting media with DAPI (Vectashield, catalog number: H-1500)

  43. Fractionation buffer (see Recipes)

  44. SDS-detergent lysis buffer (see Recipes)

  45. SDS-PAGE gel (see Recipes)


Part II. In vivo elimination of tauP301L neurofibrillary tangles

  1. Injection syringes (Becton Dickinson Medical, catalog number: 1258696)

  2. Dissection stainless steel tray (any brand)

  3. Pins or tape (any brand)

  4. Butterfly needles (Biosigma, catalog number: BSS250)

  5. 25- or 27-gauge infusion needle (KOREAVACCINE, catalog number: K201)

  6. 15 mL conical tube (Tarsons, catalog number: 546021)

  7. 1.5 mL e-tube (Axygen, catalog number: MCT-150-C)

  8. 24-well plate (Nest, catalog number: 702002, SPL, catalog number: 30024)

  9. Kim-wipe or paper tower (Yuhan-Kimberly, catalog number: 41112)

  10. Foil (SAM JIN FOIL, 30 cm × 30 m)

  11. Microscope slide (Marienfield, catalog number: 1000612)

  12. PBS (Biosesang, catalog number: P2007-1)

  13. Avertin (Sigma-Aldrich, catalog number: T48402)

  14. 0.9% saline (Sigma-Aldrich, catalog number: 08059)

  15. RIPA (Cell nest, catalog number: CNR001-0100)

  16. Protease inhibitor (Abbkine, catalog number: BMP1001)

  17. Phosphatase inhibitor (Sigma-Aldrich, catalog number: P0001)

  18. Sucrose (Sigma-Aldrich, catalog number: S0389)

  19. Sodium dodecyl sulfate (SDS) (Duchefa Biochemie, catalog number: S1377.1000)

  20. Triple-distilled water (DIW)

  21. 4% paraformaldehyde (Biosesang, catalog number: pc2031-100-00)

  22. Optional cutting temperature (OCT) compound (Sakura Tissue-Tek, catalog number: 4583)

  23. Sodium azide (Thermo Fisher Scientific, catalog number: J21610-22)

  24. Sudan black B (Sigma-Aldrich, catalog number: 199664)

  25. Hoechst (Abcam, ab228550)

  26. EtOH (DUKSAN, catalog number: 64-17-5)

  27. 0.01% PBST (see Recipes)

  28. Blocking solution (see Recipes)

  29. Injection drug (see Recipes)


Primary antibodies

  1. Rabbit polyclonal anti-LC3 (Sigma-Aldrich, catalog number: L7543, 1:10,000 diluted in PBST solution)

  2. Rabbit polyclonal anti-GAPDH (Bio World, catalog number: AP0063, 1:10,000 diluted in PBST solution)

  3. Mouse monoclonal anti-Tau5 (Invitrogen, catalog number: AHB0042, 1:5,000 diluted in PBST solution)

  4. Rabbit polyclonal anti-p-Tau (Invitrogen, catalog number: 44–752G, 1:5,000 diluted in PBST solution)

  5. AT8 antibody (Abcam, catalog number: ab210703, 1:200 diluted in the blocking solution)


Secondary antibodies

  1. Anti-rabbit IgG-HRP (Cell Signaling, catalog number: 7074, 1:10,000 diluted in PBST solution)

  2. Anti-mouse IgG-HRP (Cell Signaling, catalog number: 7076, 1:10,000 diluted in PBST solution)


Cell

  1. HeLa (ATCC, catalog number: CCL-2): the first immortal human cells to be grown in culture and the basis for countless scientific discoveries

  2. SH-SY5Y-tauP301L-GFP (Innoprot): SH-SY5Y stable cells tagged with green fluorescence and expressing tau mutant [0N4R(P301L mutant)]


Mouse

TauP301L-BiFC transgenic mouse (Shin et al., 2020): the mouse model that has two non-fluorescent compartments (hTauP301L-VN173 and hTauP301L-VC155) turning on Venus fluorescence protein upon tau assembly when they are fused with TauP301L.


Plasmid

mRFP-GFP-hTauP301L plasmid [mRFP-GFP-LC3 plasmid (Cha-Molstad et al., 2016; Dalby et al., 2004) is modified with hTauP301L]

Equipment

Part I. In vitro degradation of tauP301L aggregates

  1. Tabletop centrifuge (Eppendorf, model/catalog number: 5424R)

  2. Sonicator (SONICS vibra cel)

  3. Centrifuge (Hanil fieta 4)

  4. 37°C incubator (Hera cell vios 250i CO2 incubator)

  5. Laser scanning confocal microscope (Zeiss 510 Meta)

  6. Rocker, CR300 (Finepcr)


Part II. In vivo elimination of tauP301L neurofibrillary tangles

  1. Dissecting forceps (JEUNG DO BIO&PLANT CO., catalog number: SD-S-04PK)

  2. Tissue scissors (JEUNG DO BIO&PLANT CO., catalog number: S-49-16-SPK, S-54-10-SPK)

  3. Vascular clamp (Surtex Instruments)

  4. Micro spatula (Merck, catalog number: Z243213)

  5. Peristaltic pump (Ismatec., catalog number: ISM834)

  6. 7 mL Dounce tissue grinder (Wheaton, catalog number: 35742)

  7. Tissue grinder motor (Bel-Art, KA., catalog number: UB32-50)

  8. Polypropylene pestle (Bel-Art, BA., catalog number: 19923-0001)

  9. Rotor (FINEPCR, AG)

  10. Tabletop centrifuge (Eppendorf, catalog number: 5424R)

  11. -80°C deep freezer (Thermo Fisher Scientific, catalog number: TDE)

  12. Cryostat (Leica, catalog number: CM3050S)

  13. Cryomolds (Sakura Tissue-Tek, catalog number: 25608-922)

  14. Paintbrush (AnB, catalog number: P000EACE)

  15. ZEISS Axio Scan.Z1 (Carl Zeiss, Germany)

Software

  1. LMS image software (Zeiss LSM Image Browser (ver. 4.2.0.121))

  2. ImageJ (NIH, Bethesda)

  3. Prism 6 software (GraphPad)

Procedure

English
中文翻译

文章信息

版权信息

© 2023 The Authors; exclusive licensee Bio-protocol LLC.

如何引用

Lee, M. J., Kim, S. B., Kim, H. Y., Lee, S. J., Lee, J. S., Kwon, Y. T. and Ji, C. H. (2023). Methods to Detect AUTOphagy-Targeting Chimera (AUTOTAC)-mediated Targeted Protein Degradation in Tauopathies. Bio-protocol 13(2): e4594. DOI: 10.21769/BioProtoc.4594.

ris ris Download Citation in RIS Format

分类

药物发现 > 药物筛选

神经科学 > 神经系统疾病 > 细胞机制

细胞生物学 > 基于细胞的分析方法 > 自噬活性

您对这篇实验方法有问题吗？

在此处发布您的问题，我们将邀请本文作者来回答。同时，我们会将您的问题发布到Bio-protocol Exchange，以便寻求社区成员的帮助。

0/150

tip 提问指南

+ 问题描述

写下详细的问题描述，包括所有有助于他人回答您问题的信息（例如实验过程、条件和相关图像等）。

post 发布问题
0 Q&A
pen 提交稿件